Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis

SIMPLE SUMMARY: Accumulated evidence shows that co-prescribing proton pump inhibitors (PPIs) with major anticancer drugs is frequently harmful. We conducted a retrospective analysis of cancer patients treated with pazopanib in our health center. In this cohort of 147 patients, both the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreau-Bachelard, Camille, Letailleur, Valentin, Bompas, Emmanuelle, Soulié, Patrick, Paul, Julie, Raoul, Jean-Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564055/
https://www.ncbi.nlm.nih.gov/pubmed/36230642
http://dx.doi.org/10.3390/cancers14194721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564055/
https://www.ncbi.nlm.nih.gov/pubmed/36230642
http://dx.doi.org/10.3390/cancers14194721

Ejemplares similares